Haematology

AbbVie built one of the world's best-selling medicines in Humira, the anti-inflammatory biologic that reshaped the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease and held the position of the globe's top-revenue drug for over a decade. Spun out of Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie is listed on the New York Stock Exchange under the ticker ABBV and ranks among the largest pharmaceutical companies by market capitalisation. Immunology & Oncology Leadership Immunology remains the company's core franchise, anchored by Humira and its successors Skyrizi (risankizumab) and Rinvoq (upadacitinib), both of which have grown rapidly across multiple approved indications including plaque psoriasis, Crohn's disease and ulcerative colitis. In oncology , AbbVie markets Imbruvica (ibrutinib), a BTK inhibitor developed in partnership with Janssen, and Venclexta (venetoclax), a BCL-2 inhibitor co-developed with Roche, both indicated for certain blood cancers including chronic lymphocytic leukaemia. Neuroscience & Aesthetics Portfolio AbbVie significantly broadened its therapeutic reach with the 2020 acquisition of Allergan, one of the largest pharmaceutical mergers in history. That transaction brought the company Botox (both therapeutic and cosmetic), the migraine portfolio including Ubrelvy and Qulipta, and a range of medical aesthetics products. The neuroscience division now spans migraine prevention, movement disorders and psychiatry, with further pipeline candidates in Parkinson's disease and mood disorders. The aesthetics business, marketed under the Allergan Aesthetics brand, positions AbbVie as a leader in a segment beyond traditional pharmaceuticals. With operations spanning more than 70 countries and a global workforce numbering in the tens of thousands, AbbVie invests heavily in research and development, maintaining a broad pipeline across immunology, oncology, neuroscience and eye care. The company is a constituent of the S&P 500 and is widely followed for its progressive dividend policy. Further information is available at abbvie.com.

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Anchored in the science of human plasma, ADMA Biologics operates as a fully vertically integrated commercial biopharmaceutical company applying patented immunotechnology to develop, manufacture, and commercialise plasma-derived biologics for patients with serious immunological disorders. Listed on NASDAQ (ticker: ADMA) and headquartered in Boca Raton, Florida, the company controls each stage of its supply chain, from plasma collection through fill-finish manufacturing and medical affairs, a model that sets it apart from conventional pharmaceutical manufacturers dependent on external plasma suppliers. Commercial Portfolio and Plasma Collection ADMA's marketed products include ASCENIV, an intravenous immunoglobulin (IVIG) indicated for primary humoral immunodeficiency in adults and adolescents; BIVIGAM, a broad-spectrum IVIG therapy; and Nabi-HB, a hyperimmune globulin targeting hepatitis B. These products are manufactured at the company's FDA-licensed facility in Boca Raton. Plasma supply is secured through ADMA BioCenters, its own network of plasma collection centres operating across the United States, which feed proprietary immunotechnology fractionation processes downstream. Contract development and manufacturing services extend the company's commercial reach, allowing third-party biopharmaceutical partners to access ADMA's specialised biologics processing infrastructure. Scientific direction is guided by a dedicated Scientific Advisory Board, and the medical affairs function supports clinician engagement, publications, and advocacy for patients living with primary immunodeficiency disease. Further information is available at admabiologics.com.

Founded in 1980 in Thousand Oaks, California, Amgen was one of the world's first biotechnology companies to industrialise the manufacture of proteins from living cells, a founding ambition that shaped modern biopharmaceuticals. Listed on Nasdaq under the ticker AMGN, Amgen has grown into one of the largest independent biotechnology companies globally, with operations spanning more than 100 countries and a workforce of tens of thousands. Core Therapy Areas and Pipeline Amgen's therapeutic focus covers oncology, haematology, cardiovascular disease, inflammation, bone health, and nephrology. The company's portfolio includes well-established products such as Enbrel for inflammatory conditions, Prolia and Xgeva for bone loss, and Repatha for cholesterol management. In oncology, its BiTE (bispecific T-cell engager) platform represents a distinctive approach to cancer immunotherapy , with Blincyto being one of the first approved BiTE molecules. The 2023 acquisition of Horizon Therapeutics expanded Amgen's rare disease capabilities, adding treatments for conditions such as thyroid eye disease and gout to its portfolio. Manufacturing and Global Infrastructure Amgen operates a substantial global manufacturing network, with large-scale biologics production facilities across the United States, Puerto Rico, Ireland, and Singapore. This internal manufacturing capability, built from the company's earliest years, gives Amgen end-to-end control over biologics production at commercial scale. The company has also invested in next-generation small molecule research alongside its biologics heritage, broadening its discovery toolkit. With decades of published research, long-standing academic and clinical partnerships, and a pipeline extending across multiple therapeutic categories, Amgen remains a central reference point for practitioners, researchers, and industry professionals working in the global pharmaceutical and biotechnology sector. Further information is available at amgen.com.

Grounded in a proprietary boron chemistry platform , AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate. The development pipeline spans haematologic diseases, infectious diseases and oncology , with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines. AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases , particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry. Further information is available at an2therapeutics.com.

argenx built its reputation on a single, unusually productive starting point: the immune systems of llamas and other camelids, which produce a class of antibodies that proved to be a powerful foundation for engineering next-generation immunology medicines. From that scientific premise, the Belgian-American company has grown into one of the most closely watched names in immunology drug development , with a commercial product, VYVGART (efgartigimod alfa), approved in multiple markets for the treatment of generalised myasthenia gravis. Founded in 2008 and headquartered in Ghent, Belgium, with significant operations in the United States and Japan, argenx is listed on Nasdaq (ARGX) and on Euronext Brussels, reflecting its transatlantic scope. The company's pipeline is centred on FcRn biology, targeting the neonatal Fc receptor to reduce disease-causing IgG antibodies in a range of serious autoimmune conditions. This mechanism underpins efgartigimod in several additional indications under investigation, as well as other early-stage programmes in the portfolio. The company operates with a focused autoimmune disease strategy rather than pursuing broad therapeutic diversification, concentrating resources on conditions where dysregulated IgG antibodies drive pathology. Target areas include neuromuscular disease, haematology, and dermatology, among others under active clinical investigation. Further information is available at argenx.com.

BeiGene is one of the few oncology-focused biopharmaceutical companies to have built genuinely global commercial and clinical operations from a foundation in China, becoming a Nasdaq- and Hong Kong-listed organisation with a presence spanning more than 45 countries. Founded in 2010 and headquartered in Beijing, with major operations hubs in Cambridge (Massachusetts), Basel, and across the Asia-Pacific region, the company has grown into one of the largest clinical-stage and commercial oncology enterprises in the world by pipeline breadth. Oncology Pipeline & Approved Medicines The company's most widely recognised asset is zanubrutinib, a BTK inhibitor marketed as Brukinsa, which has received regulatory approval in the United States, European Union, China, and numerous other markets for haematological malignancies including chronic lymphocytic leukaemia, Waldenström's macroglobulinaemia, and mantle cell lymphoma. Brukinsa is designed as a next-generation BTK inhibitor with a selectivity and dosing profile intended to address limitations observed in earlier compounds in its class. Beyond Brukinsa, BeiGene has built an extensive pipeline spanning solid tumours and blood cancers, with programmes targeting PD-1, TIGIT, PARP, and other validated oncology pathways. Manufacturing & Global Infrastructure BeiGene operates large-scale biologics manufacturing facilities in Guangzhou and has invested significantly in end-to-end commercial infrastructure, including its own sales force in the United States and China. The company conducts clinical trials across multiple continents, with a clinical operations footprint that places it among the more active sponsors in haematology and solid tumour research globally. It has also entered into significant collaboration agreements with major pharmaceutical partners, broadening access to its pipeline assets and reinforcing its commercial reach in competitive markets. The company's dual focus on innovation originating in China alongside regulatory approval and commercialisation in Western markets reflects a distinctive model that differentiates it from both traditional Western biopharma and purely domestic Chinese peers. BeiGene trades on Nasdaq under the ticker BGNE and on the Hong Kong Stock Exchange. Further information is available at beigene.com.

Bristol Myers Squibb has built its modern identity around a singular strategic conviction: that understanding the biology of serious disease at the molecular level is the fastest route to transformative medicines. The company traces its origins to 1887, and its current form emerged from the merger of Bristol-Myers and Squibb in 1989, creating one of the world's largest research-driven biopharmaceutical companies. It is listed on the New York Stock Exchange under the ticker BMY. Oncology & Immuno-Oncology Leadership The area where BMS has most visibly reshaped clinical practice is oncology , and specifically immuno-oncology. Opdivo (nivolumab) and Yervoy (ipilimumab) are among the most widely recognised checkpoint inhibitors in global oncology, having been approved across a broad range of tumour types. The company's acquisition of Celgene in 2019, one of the largest transactions in pharmaceutical history at the time, added Revlimid and a substantial haematology portfolio, reinforcing BMS's position in multiple myeloma and other blood cancers. Cardiovascular & Immunology Pipeline Beyond oncology, BMS has longstanding expertise in cardiovascular disease , with Eliquis (apixaban), developed in partnership with Pfizer, becoming one of the most prescribed oral anticoagulants worldwide. The immunology and fibrosis franchises have grown in strategic importance, with the company investing in targeted protein degradation and cell therapy as emerging modalities. CAR T platforms, brought in through the Celgene acquisition, represent a key area of next-generation oncology development. Headquartered in Princeton, New Jersey, BMS operates across more than 40 countries, with major research campuses in the United States and Europe. The company employs tens of thousands of people globally and maintains a significant presence in clinical development, running one of the pharmaceutical industry's larger late-stage trial portfolios at any given time. Its commercial and scientific scale, combined with a focused therapeutic strategy centred on serious diseases with high unmet need, places BMS among a small number of companies that consistently shape oncology, haematology and cardiovascular treatment standards worldwide. Further information is available at bms.com.

CSL Limited is one of the world's largest biotechnology companies by market capitalisation, built on more than a century of plasma science and vaccine development. Founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, the company has grown from a government research body into a global ASX- and ADR-listed biotherapeutics group operating across more than 100 countries. Plasma-Derived Therapies and Behring The company's flagship division, CSL Behring, is among the world's leading manufacturers of plasma-derived therapies , supplying immunoglobulins, albumin, coagulation factors, and specialty products to patients with rare and serious conditions including primary immune deficiencies, haemophilia, and hereditary angioedema. CSL Behring operates one of the largest plasma collection networks globally, with hundreds of donation centres across North America and Europe, underpinning a manufacturing supply chain that processes tens of millions of litres of plasma each year. Seqirus and Influenza Vaccine Leadership CSL's second major division, Seqirus, is one of the two largest influenza vaccine producers in the world. Operating high-containment manufacturing facilities in the United Kingdom, the United States, and Australia, Seqirus supplies seasonal and pandemic influenza vaccines to governments and healthcare systems globally, including longstanding contracts with national immunisation programmes. The division's cell-based and adjuvanted vaccine technologies are recognised by public health authorities as meaningful advances over traditional egg-based manufacturing. In 2022 CSL completed the acquisition of Vifor Pharma, a Swiss-headquartered specialist in iron deficiency , nephrology, and cardio-renal therapies, substantially expanding the group's product portfolio and its presence in hospital and renal care markets. CSL is headquartered in Melbourne, Australia, with major operational hubs in King of Prussia (Pennsylvania), Marburg (Germany), and Bern (Switzerland). The group invests heavily in research and development, with a pipeline spanning recombinant therapies, gene therapy, and next-generation plasma fractionation. CSL's scale, century-long heritage in biologics manufacturing, and vertically integrated plasma network position it as a critical supplier to healthcare systems managing rare, chronic, and infectious disease. Further information is available at csl.com.

Genmab pioneered the development of differentiated antibody therapeutics, built on proprietary technologies that have produced some of oncology's most commercially successful medicines. Founded in 1999 and headquartered in Copenhagen, Denmark, the company operates as a Nasdaq-listed biotechnology firm with a global footprint spanning research, development, and commercial operations across Europe, North America, and Asia. The company's portfolio strategy centres on antibody innovation , underpinned by platforms including DuoBody, which enables the creation of bispecific antibodies, and HexaBody, designed to enhance immune activation. These proprietary technologies have attracted major partnership agreements with pharmaceutical companies worldwide, establishing Genmab as a technology licensor as well as a drug developer in its own right. Genmab's most recognised contribution to oncology is daratumumab, developed in collaboration with Janssen and marketed as Darzalex, which became a standard-of-care treatment for multiple myeloma. The company has continued to build its haematology and solid tumour pipeline, with a commercial-stage portfolio that includes bispecific antibody therapies such as Epkinly (epcoritamab), co-developed with AbbVie for certain B-cell malignancies. Listed on Nasdaq under the ticker GMAB and on Nasdaq Copenhagen, Genmab occupies a distinctive position in the biotech sector: an antibody specialist that has successfully translated platform technology into approved medicines and durable industry partnerships. Further information is available at genmab.com.

Founded by Paul Janssen in Beerse, Belgium in 1953 and now operating as the pharmaceutical division of Johnson Johnson, Janssen Global stands among the world's foremost research-driven pharmaceutical organisations. The business concentrates scientific and commercial resources on discovering, developing and delivering transformative medicines across oncology, immunology, infectious diseases and neuroscience, with a particularly strong record in haematological malignancies and autoimmune conditions. Therapeutic Focus and Pipeline Depth Janssen's approved portfolio illustrates the breadth of its therapeutic reach. In oncology and haematology , Darzalex (daratumumab) has become a standard-of-care option across multiple myeloma lines, while Imbruvica (ibrutinib), developed in collaboration with AbbVie, is approved across several B-cell malignancies. Zytiga (abiraterone acetate) remains a recognised treatment in metastatic prostate cancer. In immunology, Stelara (ustekinumab) and Tremfya (guselkumab) address moderate-to-severe plaque psoriasis and other inflammatory conditions. The neuroscience portfolio includes Spravato (esketamine), a nasal-spray formulation approved for treatment-resistant depression in adults. HIV and tuberculosis medicine reflects a long-standing infectious disease commitment carried through products such as Edurant (rilpivirine) and contribution to combination regimens used globally. Global Operations and Research Infrastructure Research and development hubs span Beerse, Spring House (Pennsylvania), La Jolla (California), Leiden in the Netherlands and Shanghai, supporting a pipeline that extends from early discovery through late-stage clinical programmes. Janssen works alongside academic medical centres, biotech partners and health systems to accelerate access. As a central component of Johnson Johnson's pharmaceutical segment, operating under the J J Innovative Medicine banner from 2023, the organisation benefits from the group's global manufacturing network, regulatory infrastructure and substantial annual R D investment. Its pharmaceutical pipeline spans both small molecules and large biologics, with active programmes in areas such as solid tumours, multiple sclerosis and pulmonary arterial hypertension. Further information is available at janssen.com.

Pfizer is one of the world's largest research-based biopharmaceutical companies, with a history stretching back to 1849 and a presence in more than 125 countries. Headquartered in New York City, the company is listed on the New York Stock Exchange under the ticker PFE and is a constituent of the Dow Jones Industrial Average, reflecting its standing as a cornerstone of global healthcare. Core Therapy Areas and Pipeline Pfizer's portfolio spans oncology , internal medicine, vaccines, rare diseases, and hospital-acquired infections. The company's oncology business, built in part through the acquisition of Wyeth and later Medivation, includes targeted therapies that have become widely prescribed across breast, kidney, and lung cancers. Its vaccines division is among the largest globally, and the company's partnership with BioNTech to develop an mRNA-based vaccine during the COVID-19 pandemic brought its manufacturing and distribution capabilities to worldwide attention. The rare disease unit, operating under the Pfizer Rare Disease brand, addresses conditions with limited treatment options across haematology, neurology, and metabolic disorders. Global Scale and Manufacturing Pfizer operates one of the most extensive pharmaceutical manufacturing networks in the world, with dozens of production sites across North America, Europe, and Asia. Research and development investment consistently ranks among the highest in the industry, supporting a pipeline that at any given time includes hundreds of programmes at varying stages. The company's internal medicine portfolio includes long-established brands in cardiovascular disease, pain, and infectious disease alongside newer treatments for conditions such as atopic dermatitis. Pfizer has pursued a sustained acquisition strategy over decades, with landmark transactions including Warner-Lambert, Pharmacia, Wyeth, Hospira, and Array BioPharma, each expanding its therapeutic reach or manufacturing capacity. In 2022 the company acquired Global Blood Therapeutics and Arena Pharmaceuticals, and in 2023 completed the acquisition of Seagen, significantly strengthening its oncology pipeline with antibody-drug conjugate technologies. Further information is available at pfizer.com.